News and Announcements
Big Achievements for Proteomics in December Quarter 2015 – Full Report Available
- Published January 21, 2016 3:08PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
21st January 2016, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to provide the following update on its business activities for the three month period from 31 December 2015.
Highlights:
- PromarkerD Commercialisation progress: Company has now established active, ongoing commercialisation dialogue in key global markets – USA, China and Japan.
- US Patent granted for PromarkerD: Critical milestone in the development and commercialisation pathway, and is valid until September 2031.
- Growth in Analytical Services business: On target for year-on-year growth of 25%.
- Company awarded Health and Biotechnology Export Award at Western Australian 2015 Industry and Export Awards.
December 2015 quarter commentary
The December quarter was another solid quarter for PILL. The Company continued to ficus significant effort on the commercialisation of PromarkerD, the world’s first proteomics-derived predictive (prognostic) and diagnostic test for the diagnosis of Diabetic Kidney Disease and made further progress on this front. At the same time, the Analytical Services business continued to perform in-line with Company targets, and remains on target to deliver a 25% year-on-year growth.
To read the full announcement, please click here.